nach oben

Clinical Pharmacokinetics

Erschienen in:

08.05.2018 | Letter to the Editor

Author’s Reply to Reith: “Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen”

verfasst von: Anne van Rongen, Pyry A. J. Välitalo, Catherijne A. J. Knibbe

Erschienen in: Clinical Pharmacokinetics | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Excerpt

We are writing in response to the letter from Dr David M. Reith, henceforth referred to as ‘the letter’, commenting on a model described in the paper from van Rongen et al. [1, 2]. In short, we disagree with the letter about our conclusions being an artefact, and we argue that our results should be used to inform acetaminophen dosing. Further, we note that our conclusions were supported not only by modeling and simulation, but also by raw data and an independent statistical analysis with area under the plasma concentration–time curve (AUC) values derived by non-compartmental analysis, all of which were covered in the original report. …

Reith DM. Comment on Morbidly obese patients exhibit increased CYP2E1-mediated oxidation of acetaminophen. Clin Pharmacokinet. 2018. https://doi.org/10.1007/s40262-018-0666-1.PubMedCrossRef

van Rongen A, Valitalo PA, Peeters MY, Boerma D, Huisman FW, van Ramshorst B, et al. Morbidly obese patients exhibit increased CYP2E1-mediated oxidation of acetaminophen. Clin Pharmacokinet. 2016;55(7):833–47. https://doi.org/10.1007/s40262-015-0357-0.CrossRefPubMedPubMedCentral

Ahlers SJ, Valitalo PA, Peeters MY, Gulik L, van Dongen EP, Dahan A, et al. Morphine glucuronidation and elimination in intensive care patients: a comparison with healthy volunteers. Anesth Analg. 2015;121(5):1261–73. https://doi.org/10.1213/ANE.0000000000000936.CrossRefPubMed

Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.

Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(31):1051–65.CrossRefPubMed

Titel: Author’s Reply to Reith: “Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen”
verfasst von: Anne van Rongen
Pyry A. J. Välitalo
Catherijne A. J. Knibbe
Publikationsdatum: 08.05.2018
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 7/2018
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-018-0665-2

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism

Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention

Comment on: “Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen”

A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor